Search Results

The product title you are looking for is no longer available. Other similar products that may interest you are listed below:

Refine your Search

	Results for 'Pipeline Insight: Alzheimer's Disease'

Title	Publication Date	Price	Relevance
Pipeline and Commercial Insight: Alzheimer's Disease Scenario Forecasts Reveal Vast Market Potential	March 2008	£7600	100 %
Pipeline And Commercial Insight: Parkinson's Disease Market To Grow As First Round Of Lifecycle Management Strategies Succeed	September 2007	£7600	64 %
Commercial and Pipeline Insight: Inflammatory Bowel Disease Competition Increases for the Biologics	November 2006	£6000	63 %
Pipeline Insight: Parkinson's Disease and Restless Legs Syndrome Reformulations set to drive near-term growth	August 2006	£8695	62 %
Pipeline Insight: Orphan Diseases in CNS - Part I: Huntington's Disease	November 2007	£3800	62 %
Alzheimer Disease Therapy Area Pipeline Report	March 2009	£790	50 %
Global Market and Future Outlook for Neurodegenerative Disorder Therapies 2007, The	January 2007	£1375	39 %
Molecular Insight Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	35 %
Molecular Insight Pharmaceuticals, Inc. -Therapeutic Competitors	February 2008	£175	31.5 %
Paget's Disease Therapy Area Pipeline Report	March 2009	£790	31 %
Wilson Disease Therapy Area Pipeline Report	March 2009	£790	31 %
Gaucher's Disease Therapy Area Pipeline Report	March 2009	£790	31 %
Huntington Disease Therapy Area Pipeline Report	March 2009	£790	31 %
Parkinson Disease Therapy Area Pipeline Report	March 2009	£790	31 %
NeurogesX, Inc. -Therapeutic Competitors	February 2008	£175	30.5 %
Neurochem Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Neurologix Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Neurogenesis Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Novartis AG -Therapeutic Competitors	February 2008	£175	30.5 %
Novozymes A -Therapeutic Competitors	February 2008	£175	30.5 %
Nutrition 21 Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Nuvelo Inc. -Therapeutic Competitors	February 2008	£175	30.5 %
OXiGENE INC -Therapeutic Competitors	February 2008	£175	30.5 %
Novogen Ltd -Therapeutic Competitors	February 2008	£175	30.5 %
Novavax Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Nitromed Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Novacea Inc -Therapeutic Competitors	February 2008	£175	30.5 %
NeoPharm Inc -Therapeutic Competitors	February 2008	£175	30.5 %
NexMed Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Mylan, Inc. -Therapeutic Competitors	February 2008	£175	30.5 %
Lescarden Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Lpath Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Mannatech Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Maxygen Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Lannett Co Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Labopharm Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Inyx Inc -Therapeutic Competitors	February 2008	£175	30.5 %
IsoRay Inc -Therapeutic Competitors	February 2008	£175	30.5 %
KV Pharmaceutical Co. -Therapeutic Competitors	February 2008	£175	30.5 %
Medarex Inc -Therapeutic Competitors	February 2008	£175	30.5 %
MediciNova Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Migenix Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Modigene, Inc. -Therapeutic Competitors	February 2008	£175	30.5 %
OncoVista, Inc. -Therapeutic Competitors	February 2008	£175	30.5 %
NanoViricides, Inc. -Therapeutic Competitors	February 2008	£175	30.5 %
Micromet Inc -Therapeutic Competitors	February 2008	£175	30.5 %
MicroIslet, Inc. -Therapeutic Competitors	February 2008	£175	30.5 %
Medicure Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Medivation Inc -Therapeutic Competitors	February 2008	£175	30.5 %
MethylGene Inc -Therapeutic Competitors	February 2008	£175	30.5 %
NatureWell Inc -Therapeutic Competitors	February 2008	£175	30.5 %
POZEN Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Trimeris Inc -Therapeutic Competitors	February 2008	£175	30.5 %
ULURU Inc -Therapeutic Competitors	February 2008	£175	30.5 %
VIA Pharmaceuticals, Inc. -Therapeutic Competitors	February 2008	£175	30.5 %
VIVUS Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Theravance Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Tercica Inc -Therapeutic Competitors	February 2008	£175	30.5 %
TapImmune, Inc. -Therapeutic Competitors	February 2008	£175	30.5 %
Targacept Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Telik Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Vasogen Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Vical Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Xenoport Inc -Therapeutic Competitors	February 2008	£175	30.5 %
YM BioSciences Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Zila Inc -Therapeutic Competitors	February 2008	£175	30.5 %
ZymoGenetics Inc -Therapeutic Competitors	February 2008	£175	30.5 %
XOMA Ltd -Therapeutic Competitors	February 2008	£175	30.5 %
XELR8, Inc. -Therapeutic Competitors	February 2008	£175	30.5 %
Viragen Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Viropharma Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Wyeth -Therapeutic Competitors	February 2008	£175	30.5 %
SyntheMed Inc -Therapeutic Competitors	February 2008	£175	30.5 %
SuperGen Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Pharmacopeia, Inc. -Therapeutic Competitors	February 2008	£175	30.5 %
Pharmacyclics Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Pharmasset, Inc. -Therapeutic Competitors	February 2008	£175	30.5 %
Pharmaxis Ltd. -Therapeutic Competitors	February 2008	£175	30.5 %
Pfizer Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Peplin Ltd -Therapeutic Competitors	February 2008	£175	30.5 %
Oragenics Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Orthovita Inc -Therapeutic Competitors	February 2008	£175	30.5 %
InterMune Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Phosphagenics Ltd. -Therapeutic Competitors	February 2008	£175	30.5 %
Protalex Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Santarus Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Sepracor Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Sinobiomed Inc. -Therapeutic Competitors	February 2008	£175	30.5 %
StemCells Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Replidyne Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Renovis Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Proteo Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Psivida Ltd -Therapeutic Competitors	February 2008	£175	30.5 %
QLT Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Oncothyreon, Inc. -Therapeutic Competitors	February 2008	£175	30.5 %
Osteologix, Inc. -Therapeutic Competitors	February 2008	£175	30.5 %
Inhibitex Inc -Therapeutic Competitors	February 2008	£175	30.5 %
Peripheral Vascular Disease Therapy Area Pipeline Report	March 2009	£790	30.5 %
Gastroesophageal Reflux Disease Therapy Area Pipeline Report	March 2009	£790	30.5 %
Chronic Obstructive Pulmonary Disease Therapy Area Pipeline Report	March 2009	£790	30.5 %
Inflammatory Bowel Disease Therapy Area Pipeline Report	March 2009	£790	30.5 %
Atherosclerosis or Coronary Artery Disease Therapy Area Pipeline Report	March 2009	£790	30.5 %
Stakeholder Insight: Alzheimer's Disease Prescribing trends indicate that neurologists are not adhering to guidelines	December 2006	£8000	30.1 %
Regeneron Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Raptor Pharmaceuticals Corp. -Therapeutic Competitors	February 2008	£175	30 %
Regen Therapeutics plc -Therapeutic Competitors	February 2008	£175	30 %
Questcor Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Innovive Pharmaceuticals, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Protalix BioTherapeutics, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Progen Pharmaceuticals Ltd. -Therapeutic Competitors	February 2008	£175	30 %
Procyon Corp. -Therapeutic Competitors	February 2008	£175	30 %
Progenics Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Repligen Corporation -Therapeutic Competitors	February 2008	£175	30 %
Protherics PLC -Therapeutic Competitors	February 2008	£175	30 %
Provectus Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Rigel Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Sanguine Corp -Therapeutic Competitors	February 2008	£175	30 %
Sangamo BioSciences Inc -Therapeutic Competitors	February 2008	£175	30 %
Sanofi -Aventis -Therapeutic Competitors	February 2008	£175	30 %
Savient Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Schwarz Pharma Ag -Therapeutic Competitors	February 2008	£175	30 %
Schering -Plough Corp -Therapeutic Competitors	February 2008	£175	30 %
Samaritan Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Salix Pharmaceuticals Ltd -Therapeutic Competitors	February 2008	£175	30 %
Procter & Gamble Company -Therapeutic Competitors	February 2008	£175	30 %
Rexahn Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Roche Holdings Ltd -Therapeutic Competitors	February 2008	£175	30 %
SCOLR Pharma Inc -Therapeutic Competitors	February 2008	£175	30 %
SIGA Technologies Inc -Therapeutic Competitors	February 2008	£175	30 %
SGX Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Repros Therapeutics Inc -Therapeutic Competitors	February 2008	£175	30 %
Prana Biotechnology Ltd -Therapeutic Competitors	February 2008	£175	30 %
PDL BioPharma Inc -Therapeutic Competitors	February 2008	£175	30 %
Osiris Therapeutics Inc -Therapeutic Competitors	February 2008	£175	30 %
Oscient Pharmaceuticals Corp -Therapeutic Competitors	February 2008	£175	30 %
PacificHealth Laboratories Inc -Therapeutic Competitors	February 2008	£175	30 %
Pain Therapeutics Inc -Therapeutic Competitors	February 2008	£175	30 %
Panacos Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Palatin Technologies Inc -Therapeutic Competitors	February 2008	£175	30 %
OrthoLogic Corporation -Therapeutic Competitors	February 2008	£175	30 %
Orexigen Therapeutics, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Opexa Therapeutics Inc -Therapeutic Competitors	February 2008	£175	30 %
Onyx Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Opko Health, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Optimer Pharmaceuticals, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Orchid Chemicals & Pharmaceuticals Ltd -Therapeutic Competitors	February 2008	£175	30 %
Oramed Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Par Pharmaceutical Companies Inc -Therapeutic Competitors	February 2008	£175	30 %
Penwest Pharmaceuticals Co -Therapeutic Competitors	February 2008	£175	30 %
Point Therapeutics Inc -Therapeutic Competitors	February 2008	£175	30 %
Pluristem Therapeutics, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Polydex Pharmaceuticals Ltd -Therapeutic Competitors	February 2008	£175	30 %
Poniard Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Prescient NeuroPharma Inc -Therapeutic Competitors	February 2008	£175	30 %
SciClone Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Pipex Pharmaceuticals, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Pilot Therapeutics Holdings Inc -Therapeutic Competitors	February 2008	£175	30 %
Perrigo Company -Therapeutic Competitors	February 2008	£175	30 %
Peregrine Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Pharming Group N.V. -Therapeutic Competitors	February 2008	£175	30 %
Pharmion Corp -Therapeutic Competitors	February 2008	£175	30 %
Phytopharm PLC -Therapeutic Competitors	February 2008	£175	30 %
Pharmos Corporation -Therapeutic Competitors	February 2008	£175	30 %
Pro -Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Senetek Plc -Therapeutic Competitors	February 2008	£175	30 %
Urigen Pharmaceuticals, Inc. -Therapeutic Competitors	February 2008	£175	30 %
United Therapeutics Corporation -Therapeutic Competitors	February 2008	£175	30 %
Unigene Laboratories Inc -Therapeutic Competitors	February 2008	£175	30 %
Valeant Pharmaceuticals International -Therapeutic Competitors	February 2008	£175	30 %
Vanda Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Vernalis Plc ADR -Therapeutic Competitors	February 2008	£175	30 %
Vaso Active Pharmaceuticals -Therapeutic Competitors	February 2008	£175	30 %
USANA Health Sciences Inc -Therapeutic Competitors	February 2008	£175	30 %
Trubion Pharmaceuticals Inc. -Therapeutic Competitors	February 2008	£175	30 %
The Quigley Corporation -Therapeutic Competitors	February 2008	£175	30 %
The Medicines Company -Therapeutic Competitors	February 2008	£175	30 %
Threshold Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Titan Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Transition Therapeutics Inc. -Therapeutic Competitors	February 2008	£175	30 %
TorreyPines Therapeutics, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Vertex Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
ViRexx Medical Corp -Therapeutic Competitors	February 2008	£175	30 %
World Health Energy, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Women First Healthcare Inc. -Therapeutic Competitors	February 2008	£175	30 %
XTL Biopharmaceuticals Ltd -Therapeutic Competitors	February 2008	£175	30 %
Xechem International Inc. -Therapeutic Competitors	February 2008	£175	30 %
deCODE genetics Inc -Therapeutic Competitors	February 2008	£175	30 %
ZIOPHARM Oncology Inc -Therapeutic Competitors	February 2008	£175	30 %
Watson Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Warner Chilcott Limited -Therapeutic Competitors	February 2008	£175	30 %
Vion Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
VioQuest Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Viral Genetics Inc -Therapeutic Competitors	February 2008	£175	30 %
Vital Living Inc -Therapeutic Competitors	February 2008	£175	30 %
Vyteris Holdings (Nevada) Inc -Therapeutic Competitors	February 2008	£175	30 %
Vyrex Corp -Therapeutic Competitors	February 2008	£175	30 %
Teva Pharmaceutical Industries Ltd -Therapeutic Competitors	February 2008	£175	30 %
Tetragenex Pharmaceuticals, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Somaxon Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Solbec Pharmaceuticals Ltd -Therapeutic Competitors	February 2008	£175	30 %
Smith & Nephew Plc -Therapeutic Competitors	February 2008	£175	30 %
Sonus Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Spectrum Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Starpharma Holdings Ltd -Therapeutic Competitors	February 2008	£175	30 %
Spherix Incorporated -Therapeutic Competitors	February 2008	£175	30 %
SkyePharma Plc -Therapeutic Competitors	February 2008	£175	30 %
Sirtris Pharmaceuticals, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Oncolytics Biotech Inc -Therapeutic Competitors	February 2008	£175	30 %
Seattle Genetics Inc -Therapeutic Competitors	February 2008	£175	30 %
Shire plc -Therapeutic Competitors	February 2008	£175	30 %
Simcere Pharmaceutical Group. -Therapeutic Competitors	February 2008	£175	30 %
Sinovac Biotech Ltd -Therapeutic Competitors	February 2008	£175	30 %
Sinofresh Healthcare Inc -Therapeutic Competitors	February 2008	£175	30 %
Stellar Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Stem Cell Innovations Inc -Therapeutic Competitors	February 2008	£175	30 %
Synvista Therapeutics, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Synthetic Blood International Inc -Therapeutic Competitors	February 2008	£175	30 %
Tapestry Pharmaceuticals, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Targanta Therapeutics Corp. -Therapeutic Competitors	February 2008	£175	30 %
Taro Pharmaceutical Industries Ltd -Therapeutic Competitors	February 2008	£175	30 %
Targeted Genetics Corp -Therapeutic Competitors	February 2008	£175	30 %
Synta Pharmaceuticals Corp. -Therapeutic Competitors	February 2008	£175	30 %
Synovics Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Sucampo Pharmaceuticals, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Stryker Corp -Therapeutic Competitors	February 2008	£175	30 %
Sunesis Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Swiss Medica Inc -Therapeutic Competitors	February 2008	£175	30 %
Symbollon Pharmaceuticals Inc CL A -Therapeutic Competitors	February 2008	£175	30 %
Sygnis Pharma AG -Therapeutic Competitors	February 2008	£175	30 %
Sciele Pharma, Inc. -Therapeutic Competitors	February 2008	£175	30 %
RegeneRx Biopharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Merck & Co Inc -Therapeutic Competitors	February 2008	£175	30 %
Mentor Corporation -Therapeutic Competitors	February 2008	£175	30 %
Metabasis Therapeutics Inc -Therapeutic Competitors	February 2008	£175	30 %
Metabolic Pharmaceuticals Ltd. -Therapeutic Competitors	February 2008	£175	30 %
MiddleBrook Pharmaceuticals, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Memory Pharmaceuticals Corp -Therapeutic Competitors	February 2008	£175	30 %
Meldex International Plc -Therapeutic Competitors	February 2008	£175	30 %
Matrixx Initiatives Inc -Therapeutic Competitors	February 2008	£175	30 %
Marshall Edwards Inc -Therapeutic Competitors	February 2008	£175	30 %
Inovio Biomedical Corp -Therapeutic Competitors	February 2008	£175	30 %
Med Gen Inc -Therapeutic Competitors	February 2008	£175	30 %
Medicis Pharmaceutical Corp -Therapeutic Competitors	February 2008	£175	30 %
Millennium Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Minrad International Inc -Therapeutic Competitors	February 2008	£175	30 %
NPS Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Myriad Genetics Inc -Therapeutic Competitors	February 2008	£175	30 %
Nabi Biopharmaceuticals -Therapeutic Competitors	February 2008	£175	30 %
Nastech Pharmaceutical Co Inc -Therapeutic Competitors	February 2008	£175	30 %
Nektar Therapeutics -Therapeutic Competitors	February 2008	£175	30 %
Mymetics Corporation -Therapeutic Competitors	February 2008	£175	30 %
InSite Vision Incorporated -Therapeutic Competitors	February 2008	£175	30 %
Indevus Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Miravant Medical Technologies -Therapeutic Competitors	February 2008	£175	30 %
Incyte Corporation -Therapeutic Competitors	February 2008	£175	30 %
Momenta Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Johnson & Johnson -Therapeutic Competitors	February 2008	£175	30 %
Insmed Incorporated -Therapeutic Competitors	February 2008	£175	30 %
MannKind Corp -Therapeutic Competitors	February 2008	£175	30 %
Interpharm Holdings Inc -Therapeutic Competitors	February 2008	£175	30 %
Introgen Therapeutics Inc -Therapeutic Competitors	February 2008	£175	30 %
King Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Kosan Biosciences Incorporated -Therapeutic Competitors	February 2008	£175	30 %
Kyto BioPharma Inc -Therapeutic Competitors	February 2008	£175	30 %
Inflazyme Pharmaceuticals Ltd. -Therapeutic Competitors	February 2008	£175	30 %
Iomai Corp -Therapeutic Competitors	February 2008	£175	30 %
Keryx Biopharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Jazz Pharmaceuticals, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Javelin Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Infinity Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Isis Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
LAM Pharmaceutical Corp -Therapeutic Competitors	February 2008	£175	30 %
La Jolla Pharmaceutical Co -Therapeutic Competitors	February 2008	£175	30 %
Lotus Pharmaceuticals, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Lorus Therapeutics Inc -Therapeutic Competitors	February 2008	£175	30 %
MGI Pharma Inc -Therapeutic Competitors	February 2008	£175	30 %
MacroChem Corporation -Therapeutic Competitors	February 2008	£175	30 %
Manhattan Pharmaceuticals Inc. -Therapeutic Competitors	February 2008	£175	30 %
Inspire Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
IntelGenx Technologies Corp. -Therapeutic Competitors	February 2008	£175	30 %
Lee Pharmaceuticals -Therapeutic Competitors	February 2008	£175	30 %
Intellect Neurosciences, Inc. -Therapeutic Competitors	February 2008	£175	30 %
Lev Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Lexicon Pharmaceuticals, Inc -Therapeutic Competitors	February 2008	£175	30 %
Ligand Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Neose Technologies Inc -Therapeutic Competitors	February 2008	£175	30 %
MultiCell Technologies Inc -Therapeutic Competitors	February 2008	£175	30 %
Noven Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Novo -Nordisk A -Therapeutic Competitors	February 2008	£175	30 %
Novelos Therapeutics Inc -Therapeutic Competitors	February 2008	£175	30 %
Novadel Pharma Inc -Therapeutic Competitors	February 2008	£175	30 %
North American Scientific Inc -Therapeutic Competitors	February 2008	£175	30 %
Northwest Biotherapeutics Inc -Therapeutic Competitors	February 2008	£175	30 %
Nucryst Pharmaceuticals Corp -Therapeutic Competitors	February 2008	£175	30 %
Nutra Pharma Corp -Therapeutic Competitors	February 2008	£175	30 %
Oculus Innovative Sciences Inc -Therapeutic Competitors	February 2008	£175	30 %
Omrix Biopharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
OXIS International Inc -Therapeutic Competitors	February 2008	£175	30 %
OSI Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Nventa Biopharmaceuticals Corp -Therapeutic Competitors	February 2008	£175	30 %
Nymox Pharmaceutical Corporation -Therapeutic Competitors	February 2008	£175	30 %
Nile Therapeutics, Inc -Therapeutic Competitors	February 2008	£175	30 %
Northfield Laboratories Inc -Therapeutic Competitors	February 2008	£175	30 %
Neurogen Corporation -Therapeutic Competitors	February 2008	£175	30 %
Neurocrine Biosciences Inc -Therapeutic Competitors	February 2008	£175	30 %
Neuro -Hitech Pharmaceuticals Inc -Therapeutic Competitors	February 2008	£175	30 %
Neurobiological Technologies Inc -Therapeutic Competitors	February 2008	£175	30 %
Respiratory and Pulmonary System - Chronic Obstructive Pulmonary Disease Drug Pipeline Report	February 2008	£1495	29.5 %
Flamel Technologies SA ADS-Therapeutic Competitors	March 2009	£185	28 %
Panacos Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Evotec AG-Therapeutic Competitors	March 2009	£185	28 %
Exelixis Inc-Therapeutic Competitors	March 2009	£185	28 %
Par Pharmaceutical Companies Inc-Therapeutic Competitors	March 2009	£185	28 %
PanGenex Corporation-Therapeutic Competitors	March 2009	£185	28 %
ONI BioPharma, Inc.-Therapeutic Competitors	March 2009	£185	28 %
OncoVista Innovative Therapies, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Penwest Pharmaceuticals Co-Therapeutic Competitors	March 2009	£185	28 %
Pain Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
PDL BioPharma Inc-Therapeutic Competitors	March 2009	£185	28 %
Oncolin Therapeutics, Inc.-Therapeutic Competitors	March 2009	£185	28 %
EpiCept Corp-Therapeutic Competitors	March 2009	£185	28 %
Oxygen Biotherapeutics, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Eugene Science Inc-Therapeutic Competitors	March 2009	£185	28 %
POZEN Inc-Therapeutic Competitors	March 2009	£185	28 %
Eurand N.V.-Therapeutic Competitors	March 2009	£185	28 %
Genentech Inc-Therapeutic Competitors	March 2009	£185	28 %
PacificHealth Laboratories Inc-Therapeutic Competitors	March 2009	£185	28 %
Nymox Pharmaceutical Corporation-Therapeutic Competitors	March 2009	£185	28 %
Mymetics Corporation-Therapeutic Competitors	March 2009	£185	28 %
Pharming Group N.V.-Therapeutic Competitors	March 2009	£185	28 %
Pharmacyclics Inc-Therapeutic Competitors	March 2009	£185	28 %
PharmAthene, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Pfizer Inc-Therapeutic Competitors	March 2009	£185	28 %
Pharmos Corporation-Therapeutic Competitors	March 2009	£185	28 %
Phytopharm PLC-Therapeutic Competitors	March 2009	£185	28 %
Pluristem Therapeutics, Inc.-Therapeutic Competitors	March 2009	£185	28 %
XELR8, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Oculus Innovative Sciences Inc-Therapeutic Competitors	March 2009	£185	28 %
SCOLR Pharma Inc-Therapeutic Competitors	March 2009	£185	28 %
Modigene, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Minrad International Inc-Therapeutic Competitors	March 2009	£185	28 %
OXIS International Inc-Therapeutic Competitors	March 2009	£185	28 %
Mylan, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Myriad Genetics Inc-Therapeutic Competitors	March 2009	£185	28 %
OSI Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Peregrine Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
OXiGENE INC-Therapeutic Competitors	March 2009	£185	28 %
Momenta Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Perrigo Company-Therapeutic Competitors	March 2009	£185	28 %
MultiCell Technologies Inc-Therapeutic Competitors	March 2009	£185	28 %
Peplin Ltd-Therapeutic Competitors	March 2009	£185	28 %
Osteologix, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Oramed Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Optimer Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Opko Health, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Opexa Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
NovaBay Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Nutrition 21 Inc-Therapeutic Competitors	March 2009	£185	28 %
Orchid Chemicals & Pharmaceuticals Ltd-Therapeutic Competitors	March 2009	£185	28 %
North American Scientific Inc-Therapeutic Competitors	March 2009	£185	28 %
Northfield Laboratories Inc-Therapeutic Competitors	March 2009	£185	28 %
Northwest Biotherapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
Nutra Pharma Corp-Therapeutic Competitors	March 2009	£185	28 %
Onyx Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Novo-Nordisk A-Therapeutic Competitors	March 2009	£185	28 %
Novogen Ltd-Therapeutic Competitors	March 2009	£185	28 %
Novozymes A-Therapeutic Competitors	March 2009	£185	28 %
NuRx Pharmaceuticals, Inc-Therapeutic Competitors	March 2009	£185	28 %
Noven Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Novelos Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
Oncothyreon, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Novadel Pharma Inc-Therapeutic Competitors	March 2009	£185	28 %
Novartis AG-Therapeutic Competitors	March 2009	£185	28 %
Novavax Inc-Therapeutic Competitors	March 2009	£185	28 %
Nitromed Inc-Therapeutic Competitors	March 2009	£185	28 %
Nile Therapeutics, Inc-Therapeutic Competitors	March 2009	£185	28 %
Nektar Therapeutics-Therapeutic Competitors	March 2009	£185	28 %
NeoPharm Inc-Therapeutic Competitors	March 2009	£185	28 %
OncoGenex Pharmaceuticals Inc.-Therapeutic Competitors	March 2009	£185	28 %
Osiris Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
NatureWell Inc-Therapeutic Competitors	March 2009	£185	28 %
Oncolytics Biotech Inc-Therapeutic Competitors	March 2009	£185	28 %
Nucryst Pharmaceuticals Corp-Therapeutic Competitors	March 2009	£185	28 %
NPS Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Nabi Biopharmaceuticals-Therapeutic Competitors	March 2009	£185	28 %
NanoViricides, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Oscient Pharmaceuticals Corp-Therapeutic Competitors	March 2009	£185	28 %
Orexigen Therapeutics, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Neurogenesis Inc-Therapeutic Competitors	March 2009	£185	28 %
NeurogesX, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Neurologix Inc-Therapeutic Competitors	March 2009	£185	28 %
NexMed Inc-Therapeutic Competitors	March 2009	£185	28 %
Neurogen Corporation-Therapeutic Competitors	March 2009	£185	28 %
Neurocrine Biosciences Inc-Therapeutic Competitors	March 2009	£185	28 %
Ore Pharmaceuticals Inc.-Therapeutic Competitors	March 2009	£185	28 %
Neose Technologies Inc-Therapeutic Competitors	March 2009	£185	28 %
Neuro-Hitech Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Neurobiological Technologies Inc-Therapeutic Competitors	March 2009	£185	28 %
Enzon Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
La Jolla Pharmaceutical Co-Therapeutic Competitors	March 2009	£185	28 %
Immunomedics Inc-Therapeutic Competitors	March 2009	£185	28 %
ImmunoGen Inc-Therapeutic Competitors	March 2009	£185	28 %
Medivation Inc-Therapeutic Competitors	March 2009	£185	28 %
Immunosyn Corporation-Therapeutic Competitors	March 2009	£185	28 %
Geron Corporation-Therapeutic Competitors	March 2009	£185	28 %
ImmunoCellular Therapeutics, Ltd.-Therapeutic Competitors	March 2009	£185	28 %
Immtech Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Gilead Sciences Inc-Therapeutic Competitors	March 2009	£185	28 %
MannKind Corp-Therapeutic Competitors	March 2009	£185	28 %
Idera Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Imagenetix Inc-Therapeutic Competitors	March 2009	£185	28 %
Imarx Therapeutics, Inc.-Therapeutic Competitors	March 2009	£185	28 %
InNexus Biotechnology Inc-Therapeutic Competitors	March 2009	£185	28 %
GeoVax Labs Inc-Therapeutic Competitors	March 2009	£185	28 %
Merck & Co Inc-Therapeutic Competitors	March 2009	£185	28 %
Meldex International Plc-Therapeutic Competitors	March 2009	£185	28 %
Metabasis Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
Metabolic Pharmaceuticals Ltd.-Therapeutic Competitors	March 2009	£185	28 %
MethylGene Inc-Therapeutic Competitors	March 2009	£185	28 %
MDRNA, Inc.-Therapeutic Competitors	March 2009	£185	28 %
MacroChem Corporation-Therapeutic Competitors	March 2009	£185	28 %
GeoPharma Inc-Therapeutic Competitors	March 2009	£185	28 %
Manhattan Pharmaceuticals Inc.-Therapeutic Competitors	March 2009	£185	28 %
Genzyme Corporation-Therapeutic Competitors	March 2009	£185	28 %
Gentium S.p.A-Therapeutic Competitors	March 2009	£185	28 %
Mannatech Inc-Therapeutic Competitors	March 2009	£185	28 %
GlaxoSmithKline plc-Therapeutic Competitors	March 2009	£185	28 %
Medicis Pharmaceutical Corp-Therapeutic Competitors	March 2009	£185	28 %
MediciNova Inc-Therapeutic Competitors	March 2009	£185	28 %
Hollis-Eden Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
ICAgen Inc-Therapeutic Competitors	March 2009	£185	28 %
Hi-Tech Pharmacal Co Inc-Therapeutic Competitors	March 2009	£185	28 %
Medarex Inc-Therapeutic Competitors	March 2009	£185	28 %
Maxygen Inc-Therapeutic Competitors	March 2009	£185	28 %
Hologic Inc-Therapeutic Competitors	March 2009	£185	28 %
Human Genome Sciences Inc-Therapeutic Competitors	March 2009	£185	28 %
Marshall Edwards Inc-Therapeutic Competitors	March 2009	£185	28 %
Matrixx Initiatives Inc-Therapeutic Competitors	March 2009	£185	28 %
IDM Pharma Inc-Therapeutic Competitors	March 2009	£185	28 %
Polydex Pharmaceuticals Ltd-Therapeutic Competitors	March 2009	£185	28 %
Helix BioMedix Inc-Therapeutic Competitors	March 2009	£185	28 %
Hemispherx Biopharma Inc-Therapeutic Competitors	March 2009	£185	28 %
Hana Biosciences Inc-Therapeutic Competitors	March 2009	£185	28 %
Halozyme Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
H.Lundbeck AS-Therapeutic Competitors	March 2009	£185	28 %
Idenix Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Medistem, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Medicure Inc-Therapeutic Competitors	March 2009	£185	28 %
Hemobiotech Inc-Therapeutic Competitors	March 2009	£185	28 %
IR Biosciences Holdings Inc-Therapeutic Competitors	March 2009	£185	28 %
ISTA Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
MicroIslet, Inc.-Therapeutic Competitors	March 2009	£185	28 %
MAP Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
InterMune Inc-Therapeutic Competitors	March 2009	£185	28 %
Intellect Neurosciences, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Interleukin Genetics Inc-Therapeutic Competitors	March 2009	£185	28 %
GTC Biotherapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
GPC Biotech AG-Therapeutic Competitors	March 2009	£185	28 %
GTX INC-Therapeutic Competitors	March 2009	£185	28 %
GW Pharmaceuticals PLC-Therapeutic Competitors	March 2009	£185	28 %
IntelGenx Technologies Corp.-Therapeutic Competitors	March 2009	£185	28 %
Inspire Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Gedeon Richter Ltd-Therapeutic Competitors	March 2009	£185	28 %
Hospira Inc-Therapeutic Competitors	March 2009	£185	28 %
GammaCan International Inc-Therapeutic Competitors	March 2009	£185	28 %
Forticell Bioscience, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Keryx Biopharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
IsoRay Inc-Therapeutic Competitors	March 2009	£185	28 %
Isolagen Inc-Therapeutic Competitors	March 2009	£185	28 %
Cytomedix Inc-Therapeutic Competitors	March 2009	£185	28 %
Isis Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Introgen Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
Javelin Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Eli Lilly & Co-Therapeutic Competitors	March 2009	£185	28 %
KV Pharmaceutical Co.-Therapeutic Competitors	March 2009	£185	28 %
Johnson & Johnson-Therapeutic Competitors	March 2009	£185	28 %
Jazz Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Forest Laboratories Inc-Therapeutic Competitors	March 2009	£185	28 %
GenVec Inc-Therapeutic Competitors	March 2009	£185	28 %
Miravant Medical Technologies-Therapeutic Competitors	March 2009	£185	28 %
Lixte Biotechnology Holdings, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Lorus Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
Lipid Sciences Inc-Therapeutic Competitors	March 2009	£185	28 %
Genesis Pharmaceuticals Enterprises, Inc-Therapeutic Competitors	March 2009	£185	28 %
Ligand Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Lotus Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Lpath Inc-Therapeutic Competitors	March 2009	£185	28 %
InSite Vision Incorporated-Therapeutic Competitors	March 2009	£185	28 %
Incyte Corporation-Therapeutic Competitors	March 2009	£185	28 %
Genta Incorporated-Therapeutic Competitors	March 2009	£185	28 %
Indevus Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Lexicon Pharmaceuticals, Inc-Therapeutic Competitors	March 2009	£185	28 %
Generex Biotechnology Corporation-Therapeutic Competitors	March 2009	£185	28 %
Genaera Corporation-Therapeutic Competitors	March 2009	£185	28 %
Insmed Incorporated-Therapeutic Competitors	March 2009	£185	28 %
Micromet Inc-Therapeutic Competitors	March 2009	£185	28 %
MiddleBrook Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Migenix Inc-Therapeutic Competitors	March 2009	£185	28 %
Inovio Biomedical Corp.-Therapeutic Competitors	March 2009	£185	28 %
Inhibitex Inc-Therapeutic Competitors	March 2009	£185	28 %
Lescarden Inc-Therapeutic Competitors	March 2009	£185	28 %
Lee Pharmaceuticals-Therapeutic Competitors	March 2009	£185	28 %
Lannett Co Inc-Therapeutic Competitors	March 2009	£185	28 %
Infinity Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
deCODE genetics Inc-Therapeutic Competitors	March 2009	£185	28 %
Threshold Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Bronchitis Therapy Area Pipeline Report	March 2009	£790	28 %
Asthma Therapy Area Pipeline Report	March 2009	£790	28 %
Bronchospasm Therapy Area Pipeline Report	March 2009	£790	28 %
Burns Therapy Area Pipeline Report	March 2009	£790	28 %
Cachexia Therapy Area Pipeline Report	March 2009	£790	28 %
Arrhythmiasis Therapy Area Pipeline Report	March 2009	£790	28 %
Anxiety Therapy Area Pipeline Report	March 2009	£790	28 %
Acne Therapy Area Pipeline Report	March 2009	£790	28 %
Alcoholism Therapy Area Pipeline Report	March 2009	£790	28 %
Angina Therapy Area Pipeline Report	March 2009	£790	28 %
Antidote Therapy Area Pipeline Report	March 2009	£790	28 %
Caries Therapy Area Pipeline Report	March 2009	£790	28 %
Conjunctivitis Therapy Area Pipeline Report	March 2009	£790	28 %
Diphtheria Therapy Area Pipeline Report	March 2009	£790	28 %
Dysmenorrhea Therapy Area Pipeline Report	March 2009	£790	28 %
Edema Therapy Area Pipeline Report	March 2009	£790	28 %
Endometriosis Therapy Area Pipeline Report	March 2009	£790	28 %
Diarrhea Therapy Area Pipeline Report	March 2009	£790	28 %
Depression Therapy Area Pipeline Report	March 2009	£790	28 %
Constipation Therapy Area Pipeline Report	March 2009	£790	28 %
Contraception Therapy Area Pipeline Report	March 2009	£790	28 %
Cough Therapy Area Pipeline Report	March 2009	£790	28 %
Dementia Therapy Area Pipeline Report	March 2009	£790	28 %
Acidity Therapy Area Pipeline Report	March 2009	£790	28 %
AIDS Therapy Area Pipeline Report	March 2009	£790	28 %
VioQuest Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Vicor Technologies, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Vion Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Viral Genetics Inc-Therapeutic Competitors	March 2009	£185	28 %
Viropharma Inc-Therapeutic Competitors	March 2009	£185	28 %
Vical Inc-Therapeutic Competitors	March 2009	£185	28 %
Vertex Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Valeant Pharmaceuticals International-Therapeutic Competitors	March 2009	£185	28 %
Vanda Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Vaso Active Pharmaceuticals-Therapeutic Competitors	March 2009	£185	28 %
Vasogen Inc-Therapeutic Competitors	March 2009	£185	28 %
Vital Living Inc-Therapeutic Competitors	March 2009	£185	28 %
Vyteris Inc.-Therapeutic Competitors	March 2009	£185	28 %
Xenoport Inc-Therapeutic Competitors	March 2009	£185	28 %
YM BioSciences Inc.-Therapeutic Competitors	March 2009	£185	28 %
ZIOPHARM Oncology Inc-Therapeutic Competitors	March 2009	£185	28 %
ZymoGenetics, Inc.-Therapeutic Competitors	March 2009	£185	28 %
XTL Biopharmaceuticals Ltd-Therapeutic Competitors	March 2009	£185	28 %
XOMA Ltd-Therapeutic Competitors	March 2009	£185	28 %
Warner Chilcott Limited-Therapeutic Competitors	March 2009	£185	28 %
Watson Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Winston Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Wyeth-Therapeutic Competitors	March 2009	£185	28 %
Epilepsy Therapy Area Pipeline Report	March 2009	£790	28 %
Fever Therapy Area Pipeline Report	March 2009	£790	28 %
Sepsis Therapy Area Pipeline Report	March 2009	£790	28 %
Schizophrenia Therapy Area Pipeline Report	March 2009	£790	28 %
Tetanus Therapy Area Pipeline Report	March 2009	£790	28 %
Thrombosis Therapy Area Pipeline Report	March 2009	£790	28 %
Tuberculosis Therapy Area Pipeline Report	March 2009	£790	28 %
Scabies Therapy Area Pipeline Report	March 2009	£790	28 %
Restenosis Therapy Area Pipeline Report	March 2009	£790	28 %
Osteoporosis Therapy Area Pipeline Report	March 2009	£790	28 %
Pneumonia Therapy Area Pipeline Report	March 2009	£790	28 %
Poisoning Therapy Area Pipeline Report	March 2009	£790	28 %
Psoriasis Therapy Area Pipeline Report	March 2009	£790	28 %
Ulcers Therapy Area Pipeline Report	March 2009	£790	28 %
Vertigo Therapy Area Pipeline Report	March 2009	£790	28 %
Hyperlipemia Therapy Area Pipeline Report	March 2009	£790	28 %
Inflammation Therapy Area Pipeline Report	March 2009	£790	28 %
Lymphoma Therapy Area Pipeline Report	March 2009	£790	28 %
Thromboembolism Therapy Area Pipeline Report	March 2009	£790	28 %
Hemorrhage Therapy Area Pipeline Report	March 2009	£790	28 %
Dyslipidemia Therapy Area Pipeline Report	March 2009	£790	28 %
Wrinkles Therapy Area Pipeline Report	March 2009	£790	28 %
Allergy Therapy Area Pipeline Report	March 2009	£790	28 %
Anemia Therapy Area Pipeline Report	March 2009	£790	28 %
Arthritis Therapy Area Pipeline Report	March 2009	£790	28 %
Osteoarthritis Therapy Area Pipeline Report	March 2009	£790	28 %
Onychomycosis Therapy Area Pipeline Report	March 2009	£790	28 %
Hepatitis Therapy Area Pipeline Report	March 2009	£790	28 %
Hepatitis C Therapy Area Pipeline Report	March 2009	£790	28 %
Hypercalcemia Therapy Area Pipeline Report	March 2009	£790	28 %
Hypercholesterolemia Therapy Area Pipeline Report	March 2009	£790	28 %
Hyperphosphatemia Therapy Area Pipeline Report	March 2009	£790	28 %
Hepatitis B Therapy Area Pipeline Report	March 2009	£790	28 %
Hemorrhoids Therapy Area Pipeline Report	March 2009	£790	28 %
Flatulence Therapy Area Pipeline Report	March 2009	£790	28 %
Glaucoma Therapy Area Pipeline Report	March 2009	£790	28 %
Gout Therapy Area Pipeline Report	March 2009	£790	28 %
Headache Therapy Area Pipeline Report	March 2009	£790	28 %
Hypocalcemia Therapy Area Pipeline Report	March 2009	£790	28 %
Hypogonadism Therapy Area Pipeline Report	March 2009	£790	28 %
Migraine Therapy Area Pipeline Report	March 2009	£790	28 %
Neuralgia Therapy Area Pipeline Report	March 2009	£790	28 %
Neuropathy Therapy Area Pipeline Report	March 2009	£790	28 %
Obesity Therapy Area Pipeline Report	March 2009	£790	28 %
Malaria Therapy Area Pipeline Report	March 2009	£790	28 %
Ischemia Therapy Area Pipeline Report	March 2009	£790	28 %
Hypotension Therapy Area Pipeline Report	March 2009	£790	28 %
Indigestion Therapy Area Pipeline Report	March 2009	£790	28 %
Infertility Therapy Area Pipeline Report	March 2009	£790	28 %
Influenza Therapy Area Pipeline Report	March 2009	£790	28 %
VIVUS Inc-Therapeutic Competitors	March 2009	£185	28 %
VIA Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Repros Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
Repligen Corporation-Therapeutic Competitors	March 2009	£185	28 %
Rexahn Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Rigel Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Roche Holdings Ltd-Therapeutic Competitors	March 2009	£185	28 %
Replidyne Inc-Therapeutic Competitors	March 2009	£185	28 %
Regeneron Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Questcor Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Raptor Pharmaceuticals Corp.-Therapeutic Competitors	March 2009	£185	28 %
Regen Therapeutics plc-Therapeutic Competitors	March 2009	£185	28 %
RegeneRx Biopharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Rockwell Medical Technologies Inc-Therapeutic Competitors	March 2009	£185	28 %
SIGA Technologies Inc-Therapeutic Competitors	March 2009	£185	28 %
Savient Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Schering-Plough Corp-Therapeutic Competitors	March 2009	£185	28 %
SciClone Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Seattle Genetics Inc-Therapeutic Competitors	March 2009	£185	28 %
Santarus Inc-Therapeutic Competitors	March 2009	£185	28 %
Sanofi-Aventis-Therapeutic Competitors	March 2009	£185	28 %
Salix Pharmaceuticals Ltd-Therapeutic Competitors	March 2009	£185	28 %
Samaritan Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Sangamo BioSciences Inc-Therapeutic Competitors	March 2009	£185	28 %
Sanguine Corp-Therapeutic Competitors	March 2009	£185	28 %
QLT Inc-Therapeutic Competitors	March 2009	£185	28 %
Provectus Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Proteo Inc-Therapeutic Competitors	March 2009	£185	28 %
Protalix Biotherapeutics, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Proteonomix, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Psivida Ltd-Therapeutic Competitors	March 2009	£185	28 %
The Medicines Company-Therapeutic Competitors	March 2009	£185	28 %
Protalex Inc-Therapeutic Competitors	March 2009	£185	28 %
Progenics Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Prana Biotechnology Ltd-Therapeutic Competitors	March 2009	£185	28 %
Pro-Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Procter & Gamble Company-Therapeutic Competitors	March 2009	£185	28 %
Progen Pharmaceuticals Ltd.-Therapeutic Competitors	March 2009	£185	28 %
iBioPharma, Inc.-Therapeutic Competitors	March 2009	£185	28 %
3SBio Inc.-Therapeutic Competitors	March 2009	£185	28 %
Pharmasset, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Pharmaxis Ltd.-Therapeutic Competitors	March 2009	£185	28 %
Phosphagenics Ltd.-Therapeutic Competitors	March 2009	£185	28 %
PolyMedix Inc-Therapeutic Competitors	March 2009	£185	28 %
Palatin Technologies Inc-Therapeutic Competitors	March 2009	£185	28 %
Nventa Biopharmaceuticals Corp-Therapeutic Competitors	March 2009	£185	28 %
Ardea Biosciences, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Dentsply International Inc.-Therapeutic Competitors	March 2009	£185	28 %
Dr Reddys Laboratories Ltd-Therapeutic Competitors	March 2009	£185	28 %
Freedom Eye Ltd-Therapeutic Competitors	March 2009	£185	28 %
Senesco Technologies Inc-Therapeutic Competitors	March 2009	£185	28 %
Senetek Plc-Therapeutic Competitors	March 2009	£185	28 %
Teva Pharmaceutical Industries Ltd-Therapeutic Competitors	March 2009	£185	28 %
Tetragenex Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
The Quigley Corporation-Therapeutic Competitors	March 2009	£185	28 %
Theravance Inc-Therapeutic Competitors	March 2009	£185	28 %
Enzo Biochem Inc-Therapeutic Competitors	March 2009	£185	28 %
Telik Inc-Therapeutic Competitors	March 2009	£185	28 %
Taro Pharmaceutical Industries Ltd-Therapeutic Competitors	March 2009	£185	28 %
TapImmune, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Tapestry Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Targacept Inc-Therapeutic Competitors	March 2009	£185	28 %
Targeted Genetics Corp-Therapeutic Competitors	March 2009	£185	28 %
Tianyin Pharmaceutical Co., Inc.-Therapeutic Competitors	March 2009	£185	28 %
Titan Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
USANA Health Sciences Inc-Therapeutic Competitors	March 2009	£185	28 %
Unigene Laboratories Inc-Therapeutic Competitors	March 2009	£185	28 %
United Therapeutics Corporation-Therapeutic Competitors	March 2009	£185	28 %
Urigen Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
ULURU Inc-Therapeutic Competitors	March 2009	£185	28 %
Trubion Pharmaceuticals Inc.-Therapeutic Competitors	March 2009	£185	28 %
TorreyPines Therapeutics, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Transdel Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Transition Therapeutics Inc.-Therapeutic Competitors	March 2009	£185	28 %
Trimeris Inc-Therapeutic Competitors	March 2009	£185	28 %
Synvista Therapeutics, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Synta Pharmaceuticals Corp.-Therapeutic Competitors	March 2009	£185	28 %
Skinvisible Inc-Therapeutic Competitors	March 2009	£185	28 %
SkyePharma Plc-Therapeutic Competitors	March 2009	£185	28 %
Smith & Nephew Plc-Therapeutic Competitors	March 2009	£185	28 %
Somaxon Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Sinovac Biotech Ltd-Therapeutic Competitors	March 2009	£185	28 %
Sinofresh Healthcare Inc.-Therapeutic Competitors	March 2009	£185	28 %
Sepracor Inc-Therapeutic Competitors	March 2009	£185	28 %
Shire plc-Therapeutic Competitors	March 2009	£185	28 %
Simcere Pharmaceutical Group.-Therapeutic Competitors	March 2009	£185	28 %
Sinobiomed Inc.-Therapeutic Competitors	March 2009	£185	28 %
Spectrum Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Spherix Incorporated-Therapeutic Competitors	March 2009	£185	28 %
SuperGen Inc-Therapeutic Competitors	March 2009	£185	28 %
Swiss Medica Inc-Therapeutic Competitors	March 2009	£185	28 %
Sygnis Pharma AG-Therapeutic Competitors	March 2009	£185	28 %
Symbollon Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Sunesis Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Sucampo Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Starpharma Holdings Ltd-Therapeutic Competitors	March 2009	£185	28 %
Stellar Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
StemCells Inc-Therapeutic Competitors	March 2009	£185	28 %
Stryker Corp-Therapeutic Competitors	March 2009	£185	28 %
Poniard Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
BioSphere Medical Inc-Therapeutic Competitors	March 2009	£185	28 %
ArQule Inc-Therapeutic Competitors	March 2009	£185	28 %
Applied wellness Corp.-Therapeutic Competitors	March 2009	£185	28 %
Antisoma PLC-Therapeutic Competitors	March 2009	£185	28 %
Antigenics Inc-Therapeutic Competitors	March 2009	£185	28 %
Aradigm Corp-Therapeutic Competitors	March 2009	£185	28 %
Arana Therapeutics Limited-Therapeutic Competitors	March 2009	£185	28 %
Array BioPharma Inc-Therapeutic Competitors	March 2009	£185	28 %
Arno Therapeutics, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Ariad Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Arena Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Antares Pharma Inc-Therapeutic Competitors	March 2009	£185	28 %
Anika Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
Amdl Inc-Therapeutic Competitors	March 2009	£185	28 %
Amazon Biotech Inc.-Therapeutic Competitors	March 2009	£185	28 %
Amarin Corporation plc-Therapeutic Competitors	March 2009	£185	28 %
Amarillo Biosciences Inc-Therapeutic Competitors	March 2009	£185	28 %
Amicus Therapeutics, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Amylin Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Angiotech Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Anesiva, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Anavex Life Sciences Corp.-Therapeutic Competitors	March 2009	£185	28 %
Anadys Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Artes Medical, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Astellas Pharma Inc-Therapeutic Competitors	March 2009	£185	28 %
Benda Pharmaceutical, Inc-Therapeutic Competitors	March 2009	£185	28 %
Bayer Ag-Therapeutic Competitors	March 2009	£185	28 %
Baxter International Inc-Therapeutic Competitors	March 2009	£185	28 %
Bavarian Nordic AS-Therapeutic Competitors	March 2009	£185	28 %
Benitec Ltd-Therapeutic Competitors	March 2009	£185	28 %
Bio-Bridge Science Inc-Therapeutic Competitors	March 2009	£185	28 %
BioMarin Pharmaceutical Inc-Therapeutic Competitors	March 2009	£185	28 %
BioForm Medical, Inc.-Therapeutic Competitors	March 2009	£185	28 %
BioDelivery Sciences International Inc-Therapeutic Competitors	March 2009	£185	28 %
BioCryst Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Basilea Pharmaceutica AG-Therapeutic Competitors	March 2009	£185	28 %
BMP Sunstone Corp.-Therapeutic Competitors	March 2009	£185	28 %
Auriga Laboratories Inc.-Therapeutic Competitors	March 2009	£185	28 %
Athersys, Inc.-Therapeutic Competitors	March 2009	£185	28 %
AtheroGenics Inc-Therapeutic Competitors	March 2009	£185	28 %
AstraZeneca Plc-Therapeutic Competitors	March 2009	£185	28 %
AutoImmune Inc-Therapeutic Competitors	March 2009	£185	28 %
Auxilium Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
BELLUS Health Inc.-Therapeutic Competitors	March 2009	£185	28 %
Avigen Inc-Therapeutic Competitors	March 2009	£185	28 %
Avicena Group Inc-Therapeutic Competitors	March 2009	£185	28 %
Avalon Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Altus Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Alseres Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Achillion Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Access Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Accentia Biopharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Abraxis BioScience, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Acorda Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
Actelion Ltd-Therapeutic Competitors	March 2009	£185	28 %
Adherex Technologies Inc-Therapeutic Competitors	March 2009	£185	28 %
Adeona Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Acusphere Inc-Therapeutic Competitors	March 2009	£185	28 %
Acura Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Abbott Laboratories-Therapeutic Competitors	March 2009	£185	28 %
Aastrom Biosciences Inc-Therapeutic Competitors	March 2009	£185	28 %
AMAG Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
AEterna Zentaris Inc-Therapeutic Competitors	March 2009	£185	28 %
ACADIA Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
EntreMed Inc-Therapeutic Competitors	March 2009	£185	28 %
AP Pharma Inc-Therapeutic Competitors	March 2009	£185	28 %
ARYx Therapeutics, Inc.-Therapeutic Competitors	March 2009	£185	28 %
AXM Pharma Inc-Therapeutic Competitors	March 2009	£185	28 %
AVI BioPharma Inc-Therapeutic Competitors	March 2009	£185	28 %
AVAX TECHNOLOGIES INCORPORATED-Therapeutic Competitors	March 2009	£185	28 %
AVANIR Pharmaceuticals-Therapeutic Competitors	March 2009	£185	28 %
Adolor Corp-Therapeutic Competitors	March 2009	£185	28 %
Advanced Cell Technology Inc-Therapeutic Competitors	March 2009	£185	28 %
Alkermes Inc-Therapeutic Competitors	March 2009	£185	28 %
Alfacell Corp-Therapeutic Competitors	March 2009	£185	28 %
Alexza Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Alexion Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Allergan Inc-Therapeutic Competitors	March 2009	£185	28 %
Allergy Therapeutics plc-Therapeutic Competitors	March 2009	£185	28 %
AlphaRx Inc.-Therapeutic Competitors	March 2009	£185	28 %
Alnylam Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Allos Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
Alliance Pharmaceutical Corporation-Therapeutic Competitors	March 2009	£185	28 %
Alcon Inc-Therapeutic Competitors	March 2009	£185	28 %
Alchemia Ltd-Therapeutic Competitors	March 2009	£185	28 %
Adventrx Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Advaxis Inc-Therapeutic Competitors	March 2009	£185	28 %
Advanced Viral Research Corp-Therapeutic Competitors	March 2009	£185	28 %
Advanced Life Sciences Holdings Inc-Therapeutic Competitors	March 2009	£185	28 %
Aeolus Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Affymax Inc-Therapeutic Competitors	March 2009	£185	28 %
Albany Molecular Research Inc-Therapeutic Competitors	March 2009	£185	28 %
Akorn Inc-Therapeutic Competitors	March 2009	£185	28 %
Akesis Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
BioMimetic Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
Amgen Inc-Therapeutic Competitors	March 2009	£185	28 %
Cypress Bioscience Incorporated-Therapeutic Competitors	March 2009	£185	28 %
Cyplasin Biomedical Ltd.-Therapeutic Competitors	March 2009	£185	28 %
Cyclacel Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Cyanotech Corporation-Therapeutic Competitors	March 2009	£185	28 %
CytRx Corporation-Therapeutic Competitors	March 2009	£185	28 %
CytoDyn Inc-Therapeutic Competitors	March 2009	£185	28 %
Cytos Biotechnology AG-Therapeutic Competitors	March 2009	£185	28 %
Cytori Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
Cytokinetics Inc-Therapeutic Competitors	March 2009	£185	28 %
Cytogenix Inc-Therapeutic Competitors	March 2009	£185	28 %
Curis Inc-Therapeutic Competitors	March 2009	£185	28 %
CuraGen Corp-Therapeutic Competitors	March 2009	£185	28 %
Compugen Ltd-Therapeutic Competitors	March 2009	£185	28 %
CombinatoRx Inc-Therapeutic Competitors	March 2009	£185	28 %
Columbia Laboratories Inc-Therapeutic Competitors	March 2009	£185	28 %
Colgate-Palmolive Co.-Therapeutic Competitors	March 2009	£185	28 %
Corcept Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
Cordex Pharma, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Cubist Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Crucell N V-Therapeutic Competitors	March 2009	£185	28 %
Cougar Biotechnology, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Cortex Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
DARA BioSciences, Inc-Therapeutic Competitors	March 2009	£185	28 %
DOR BioPharma Inc-Therapeutic Competitors	March 2009	£185	28 %
Echo Therapeutics, Inc-Therapeutic Competitors	March 2009	£185	28 %
EPIX Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Dynavax Technologies Corp-Therapeutic Competitors	March 2009	£185	28 %
Dyax Corp-Therapeutic Competitors	March 2009	£185	28 %
Eisai Co Ltd-Therapeutic Competitors	March 2009	£185	28 %
Elan Corp Plc-Therapeutic Competitors	March 2009	£185	28 %
Endo Pharmaceuticals Holdings Inc-Therapeutic Competitors	March 2009	£185	28 %
Emisphere Technologies Inc-Therapeutic Competitors	March 2009	£185	28 %
Emergent BioSolutions Inc-Therapeutic Competitors	March 2009	£185	28 %
BioSante Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Dragon Pharmaceutical Inc-Therapeutic Competitors	March 2009	£185	28 %
Dov Pharmaceutical Inc-Therapeutic Competitors	March 2009	£185	28 %
Dendreon Corp-Therapeutic Competitors	March 2009	£185	28 %
DelSite, Inc.-Therapeutic Competitors	March 2009	£185	28 %
DUSA Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
DURECT Corporation-Therapeutic Competitors	March 2009	£185	28 %
Depomed Inc-Therapeutic Competitors	March 2009	£185	28 %
Derma Sciences Inc-Therapeutic Competitors	March 2009	£185	28 %
Dnaprint Genomics Inc-Therapeutic Competitors	March 2009	£185	28 %
Discovery Laboratories Inc-Therapeutic Competitors	March 2009	£185	28 %
Diamyd Medical AB-Therapeutic Competitors	March 2009	£185	28 %
Cobalis Corp-Therapeutic Competitors	March 2009	£185	28 %
Elite Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
CPEX Pharmaceuticals, Inc.-Therapeutic Competitors	March 2009	£185	28 %
CEL-SCI Corporation-Therapeutic Competitors	March 2009	£185	28 %
Bristol-Myers Squibb Company-Therapeutic Competitors	March 2009	£185	28 %
Biotech Holdings Ltd-Therapeutic Competitors	March 2009	£185	28 %
CV Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
Cadence Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Caraco Pharmaceutical Laboratories Ltd-Therapeutic Competitors	March 2009	£185	28 %
Capstone Therapeutics-Therapeutic Competitors	March 2009	£185	28 %
Callisto Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Biosyntech Inc-Therapeutic Competitors	March 2009	£185	28 %
Biopure Corporation-Therapeutic Competitors	March 2009	£185	28 %
Biodel Inc.-Therapeutic Competitors	March 2009	£185	28 %
BioTime Inc-Therapeutic Competitors	March 2009	£185	28 %
BioSpecifics Technologies Corp-Therapeutic Competitors	March 2009	£185	28 %
Clinuvel Pharmaceuticals Limited-Therapeutic Competitors	March 2009	£185	28 %
Biogen Idec Inc-Therapeutic Competitors	March 2009	£185	28 %
Bioheart, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Biopath Holdings, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Bionovo Inc-Therapeutic Competitors	March 2009	£185	28 %
Bioniche Life Sciences Inc-Therapeutic Competitors	March 2009	£185	28 %
CardioVascular BioTherapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
Biovail Corporation-Therapeutic Competitors	March 2009	£185	28 %
China Aoxing Pharmaceutical Co., Inc.-Therapeutic Competitors	March 2009	£185	28 %
Chemokine Therapeutics Corp-Therapeutic Competitors	March 2009	£185	28 %
Clinical Data Inc-Therapeutic Competitors	March 2009	£185	28 %
Chelsea Therapeutics International Ltd-Therapeutic Competitors	March 2009	£185	28 %
China Pharma Holdings Inc.-Therapeutic Competitors	March 2009	£185	28 %
China Sky One Medical, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Cleveland Biolabs Inc-Therapeutic Competitors	March 2009	£185	28 %
Chugai Pharmaceutical Co Ltd-Therapeutic Competitors	March 2009	£185	28 %
Cardiome Pharma Corp-Therapeutic Competitors	March 2009	£185	28 %
Chattem Inc-Therapeutic Competitors	March 2009	£185	28 %
Chemgenex Pharmaceuticals Ltd-Therapeutic Competitors	March 2009	£185	28 %
Cell Genesys Inc-Therapeutic Competitors	March 2009	£185	28 %
Cell Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
Ceragenix Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	28 %
Catalyst Pharmaceutical Partners Inc.-Therapeutic Competitors	March 2009	£185	28 %
Cardium Therapeutics Inc-Therapeutic Competitors	March 2009	£185	28 %
Celldex Therapeutics, Inc.-Therapeutic Competitors	March 2009	£185	28 %
Celgene Corporation-Therapeutic Competitors	March 2009	£185	28 %
Cephalon Inc-Therapeutic Competitors	March 2009	£185	28 %
Celsion Corp-Therapeutic Competitors	March 2009	£185	28 %
Metabolic Endocrinology - Type II Diabetes Drug Pipeline Report	February 2008	£1495	27.5 %
Metabolic Endocrinology - Vitamin Deficiency Drug Pipeline Report	February 2008	£995	27.5 %
Non-Hodgkin Lymphoma Drug Pipeline Report	February 2008	£1495	27.5 %
Metabolic Endocrinology - Type I Diabetes Drug Pipeline Report	February 2008	£995	27.5 %
Multiple Myeloma Drug Pipeline Report	February 2008	£1495	27.5 %
Musculo-Skeletal-Disorders - Muscle Pain Drug Pipeline Report	February 2008	£995	27.5 %
Metabolic Endocrinology - Obesity Drug Pipeline Report	February 2008	£1495	27.5 %
Vernalis Plc ADR-Therapeutic Competitors	March 2009	£185	27.5 %
Musculo-Skeletal-Disorders - Osteoarthritis Drug Pipeline Report	February 2008	£1495	27.5 %
Musculo-Skeletal-Disorders - Gout Drug Pipeline Report	February 2008	£995	27.5 %
Kidneys and Genito-Urinary System - Hyperphosphatemia Drug Pipeline Report	February 2008	£995	27.5 %
Kidneys and Genito-Urinary System - Urinary Incontinence Drug Pipeline Report	February 2008	£995	27.5 %
Kidneys and Genito-Urinary System - Overactive Bladder Drug Pipeline Report	February 2008	£995	27.5 %
Kidneys and Genito-Urinary System - Kidney Stones Drug Pipeline Report	February 2008	£995	27.5 %
Ophthalmology and Optometry - Conjunctivitis Drug Pipeline Report	February 2008	£995	27.5 %
Liver Cancer Drug Pipeline Report	February 2008	£995	27.5 %
Melanoma or Skin Cancer Drug Pipeline Report	February 2008	£1495	27.5 %
Metabolic Endocrinology - Hypocalcemia Drug Pipeline Report	February 2008	£995	27.5 %
Metabolic Endocrinology - Hypercalcemia Drug Pipeline Report	February 2008	£995	27.5 %
Metabolic Endocrinology - Diabetic Neuropathy Drug Pipeline Report	February 2008	£995	27.5 %
Metabolic Endocrinology - Cachexia Drug Pipeline Report	February 2008	£995	27.5 %
Metabolic Endocrinology - Hypogonadism Drug Pipeline Report	February 2008	£995	27.5 %
Women's Health - Contraception Drug Pipeline Report	February 2008	£995	27.5 %
Substance Abuse - Antidote Drug Pipeline Report	February 2008	£995	27.5 %
Substance Abuse - Alcoholism Drug Pipeline Report	February 2008	£995	27.5 %
Respiratory and Pulmonary System - Nasal congestion Drug Pipeline Report	February 2008	£995	27.5 %
Respiratory and Pulmonary System - Cystic Fibrosis Drug Pipeline Report	February 2008	£995	27.5 %
Substance Abuse - Poisoning Drug Pipeline Report	February 2008	£995	27.5 %
Substance Abuse - Smoking Cessation Drug Pipeline Report	February 2008	£995	27.5 %
Women's Health - Menopausal Symptoms Drug Pipeline Report	February 2008	£995	27.5 %
Women's Health - Infertility Drug Pipeline Report	February 2008	£995	27.5 %
Women's Health - Endometriosis Drug Pipeline Report	February 2008	£995	27.5 %
Kidneys and Genito-Urinary System - Erectile Dysfunction Drug Pipeline Report	February 2008	£995	27.5 %
Respiratory and Pulmonary System - Cough Drug Pipeline Report	February 2008	£995	27.5 %
Respiratory and Pulmonary System - Bronchospasm Drug Pipeline Report	February 2008	£995	27.5 %
Ophthalmology and Optometry - Ocular Inflammation Drug Pipeline Report	February 2008	£995	27.5 %
Ophthalmology and Optometry - Macular Degeneration Drug Pipeline Report	February 2008	£1495	27.5 %
Ophthalmology and Optometry - Glaucoma Drug Pipeline Report	February 2008	£1495	27.5 %
Ophthalmology and Optometry - Eye Infections Drug Pipeline Report	February 2008	£995	27.5 %
Ovarian Cancer Drug Pipeline Report	February 2008	£1495	27.5 %
Pancreatic Cancer Drug Pipeline Report	February 2008	£1495	27.5 %
Respiratory and Pulmonary System - Bronchitis Drug Pipeline Report	February 2008	£995	27.5 %
Respiratory and Pulmonary System - Asthma Drug Pipeline Report	February 2008	£1495	27.5 %
Prostate Cancer Drug Pipeline Report	February 2008	£1495	27.5 %
Ophthalmology and Optometry - Dry Eyes Drug Pipeline Report	February 2008	£995	27.5 %
Atrial Fibrillation Therapy Area Pipeline Report	March 2009	£790	27.5 %
Infections - Bacterial Infections Drug Pipeline Report	February 2008	£1495	27.5 %
Infections - AIDS HIV Drug Pipeline Report	February 2008	£1495	27.5 %
Cystic Fibrosis Therapy Area Pipeline Report	March 2009	£790	27.5 %
Fungal Infections or Candidiasis Therapy Area Pipeline Report	March 2009	£790	27.5 %
Congestive Heart Failure Therapy Area Pipeline Report	March 2009	£790	27.5 %
Infections - Ear Infections Drug Pipeline Report	February 2008	£995	27.5 %
Infections - Hepatitis B Drug Pipeline Report	February 2008	£1495	27.5 %
Infections - Helminthic Infestations Drug Pipeline Report	February 2008	£995	27.5 %
Infections - Fungal Infections or Candidiasis Drug Pipeline Report	February 2008	£1495	27.5 %
Infections - Fever Drug Pipeline Report	February 2008	£995	27.5 %
Dental Pain Therapy Area Pipeline Report	March 2009	£790	27.5 %
Multiple Sclerosis Therapy Area Pipeline Report	March 2009	£790	27.5 %
Ear Infections Therapy Area Pipeline Report	March 2009	£790	27.5 %
Eye Infections Therapy Area Pipeline Report	March 2009	£790	27.5 %
Erectile Dysfunction Therapy Area Pipeline Report	March 2009	£790	27.5 %
Women's Health - Vaginal Infections Drug Pipeline Report	February 2008	£995	27.5 %
Menopausal Symptoms Therapy Area Pipeline Report	March 2009	£790	27.5 %
Dry Eye Syndrome Therapy Area Pipeline Report	March 2009	£790	27.5 %
Diabetic Nephropathy Therapy Area Pipeline Report	March 2009	£790	27.5 %
Diabetic Neuropathy Therapy Area Pipeline Report	March 2009	£790	27.5 %
Diabetic Retinopathy Therapy Area Pipeline Report	March 2009	£790	27.5 %
Memory Impairment Therapy Area Pipeline Report	March 2009	£790	27.5 %
Infections - Hepatitis C Drug Pipeline Report	February 2008	£1495	27.5 %
Bipolar Disorder Therapy Area Pipeline Report	March 2009	£790	27.5 %
Kidneys and Genito-Urinary System - Diabetic Nephropathy Drug Pipeline Report	February 2008	£995	27.5 %
Abnormal Uterine Bleeding Therapy Area Pipeline Report	March 2009	£790	27.5 %
Kidney Cancer Drug Pipeline Report	February 2008	£1495	27.5 %
Acute Coronary Syndromes Therapy Area Pipeline Report	March 2009	£790	27.5 %
Muscle Pain Therapy Area Pipeline Report	March 2009	£790	27.5 %
Myasthenia Gravis Therapy Area Pipeline Report	March 2009	£790	27.5 %
Nausea and Vomiting Therapy Area Pipeline Report	March 2009	£790	27.5 %
Nasal congestion Therapy Area Pipeline Report	March 2009	£790	27.5 %
Myocardial Infarction Therapy Area Pipeline Report	March 2009	£790	27.5 %
Gingivitis or Periodontitis Therapy Area Pipeline Report	March 2009	£790	27.5 %
Acute Intestinal Amebiasis Therapy Area Pipeline Report	March 2009	£790	27.5 %
Infections - Viral Infections Drug Pipeline Report	February 2008	£995	27.5 %
Infections - Pneumonia Drug Pipeline Report	February 2008	£1495	27.5 %
Infections - Malaria Drug Pipeline Report	February 2008	£995	27.5 %
Infections - Influenza Drug Pipeline Report	February 2008	£1495	27.5 %
Benign Prostatic Hyperplasia Therapy Area Pipeline Report	March 2009	£790	27.5 %
Infections - Staphylococcal Infections Drug Pipeline Report	February 2008	£1495	27.5 %
Infections - Tuberculosis Drug Pipeline Report	February 2008	£995	27.5 %
Alopecia (Hair Loss) Therapy Area Pipeline Report	March 2009	£790	27.5 %
Infections - Urinary Tract Infections Drug Pipeline Report	February 2008	£995	27.5 %
Amyotrophic Lateral Sclerosis Therapy Area Pipeline Report	March 2009	£790	27.5 %
Growth Hormone Deficiency Therapy Area Pipeline Report	March 2009	£790	27.5 %
Rheumatoid Arthritis Therapy Area Pipeline Report	March 2009	£790	27.5 %
Throat Infection Therapy Area Pipeline Report	March 2009	£790	27.5 %
Autoimmune Diseases Therapy Area Pipeline Report	March 2009	£790	27.5 %
Insomnia or Sleep Disorders Therapy Area Pipeline Report	March 2009	£790	27.5 %
Kidney Stones Therapy Area Pipeline Report	March 2009	£790	27.5 %
Type I Diabetes Therapy Area Pipeline Report	March 2009	£790	27.5 %
Turner's Syndrome Therapy Area Pipeline Report	March 2009	£790	27.5 %
Bladder Cancer Therapy Area Pipeline Report	March 2009	£790	27.5 %
Brain Tumor Therapy Area Pipeline Report	March 2009	£790	27.5 %
Transplant Rejection or Transplantation Therapy Area Pipeline Report	March 2009	£790	27.5 %
Seborrheic Dermatitis Therapy Area Pipeline Report	March 2009	£790	27.5 %
Breast Cancer Therapy Area Pipeline Report	March 2009	£790	27.5 %
Smoking Cessation Therapy Area Pipeline Report	March 2009	£790	27.5 %
Staphylococcal Infections Therapy Area Pipeline Report	March 2009	£790	27.5 %
Type II Diabetes Therapy Area Pipeline Report	March 2009	£790	27.5 %
Ulcerative Colitis Therapy Area Pipeline Report	March 2009	£790	27.5 %
Myelodysplastic Syndrome Therapy Area Pipeline Report	March 2009	£790	27.5 %
Urinary Tract Infections Therapy Area Pipeline Report	March 2009	£790	27.5 %
Varicose Veins Therapy Area Pipeline Report	March 2009	£790	27.5 %
Multiple Myeloma Therapy Area Pipeline Report	March 2009	£790	27.5 %
Liver Cancer Therapy Area Pipeline Report	March 2009	£790	27.5 %
Melanoma or Skin Cancer Therapy Area Pipeline Report	March 2009	£790	27.5 %
Non-Hodgkin Lymphoma Therapy Area Pipeline Report	March 2009	£790	27.5 %
Viral Infections Therapy Area Pipeline Report	March 2009	£790	27.5 %
Wounds or Wound Dressing Therapy Area Pipeline Report	March 2009	£790	27.5 %
Labor and Delivery Therapy Area Pipeline Report	March 2009	£790	27.5 %
Female Sexual Dysfunction Therapy Area Pipeline Report	March 2009	£790	27.5 %
Vitamin Deficiency Therapy Area Pipeline Report	March 2009	£790	27.5 %
Urinary Incontinence Therapy Area Pipeline Report	March 2009	£790	27.5 %
Vaginal Infections Therapy Area Pipeline Report	March 2009	£790	27.5 %
Hormone Replacement Therapy Therapy Area Pipeline Report	March 2009	£790	27.5 %
Biocon Ltd-Therapeutic Competitors	March 2009	£185	27.5 %
Ocular Inflammation Therapy Area Pipeline Report	March 2009	£790	27.5 %
Macular Degeneration Therapy Area Pipeline Report	March 2009	£790	27.5 %
Opium Addiction Therapy Area Pipeline Report	March 2009	£790	27.5 %
Ovarian Cancer Therapy Area Pipeline Report	March 2009	£790	27.5 %
Kidney Cancer Therapy Area Pipeline Report	March 2009	£790	27.5 %
King Pharmaceuticals Inc-Therapeutic Competitors	March 2009	£185	27.5 %
Irritable Bowel Syndrome Therapy Area Pipeline Report	March 2009	£790	27.5 %
Labopharm Inc-Therapeutic Competitors	March 2009	£185	27.5 %
Obsessive-Compulsive Disorder Therapy Area Pipeline Report	March 2009	£790	27.5 %
Ocular Hypertension Therapy Area Pipeline Report	March 2009	£790	27.5 %
Helminthic Infestations Therapy Area Pipeline Report	March 2009	£790	27.5 %
Respiratory Tract Infections Therapy Area Pipeline Report	March 2009	£790	27.5 %
Overactive Bladder Therapy Area Pipeline Report	March 2009	£790	27.5 %
Psychotic Disorders Therapy Area Pipeline Report	March 2009	£790	27.5 %
Intermittent Claudication Therapy Area Pipeline Report	March 2009	£790	27.5 %
Electrolyte Deficiencies Therapy Area Pipeline Report	March 2009	£790	27.5 %
Pulmonary Fibrosis Therapy Area Pipeline Report	March 2009	£790	27.5 %
Pulmonary Hypertension Therapy Area Pipeline Report	March 2009	£790	27.5 %
Head and Neck Cancer Therapy Area Pipeline Report	March 2009	£790	27.5 %
Prostate Cancer Therapy Area Pipeline Report	March 2009	£790	27.5 %
Pancreatic Cancer Therapy Area Pipeline Report	March 2009	£790	27.5 %
Gastrointestinal (Stomach) Cancer Therapy Area Pipeline Report	March 2009	£790	27.5 %
Panic Disorder Therapy Area Pipeline Report	March 2009	£790	27.5 %
Postmenopausal Osteoporosis Therapy Area Pipeline Report	March 2009	£790	27.5 %
Attention Deficit Disorder with Hyperactivity Therapy Area Pipeline Report	March 2009	£790	27 %
Kidneys and Genito-Urinary System - Benign Prostatic Hyperplasia Drug Pipeline Report	February 2008	£995	27 %
Infections - Herpes Simplex Virus Infection Drug Pipeline Report	February 2008	£995	27 %
Hemophilia or Blood Coagulation Disorders Therapy Area Pipeline Report	March 2009	£790	27 %
Colorectal Cancer or Colon Cancer Therapy Area Pipeline Report	March 2009	£790	27 %
Tinea Pedis (Athlete's Foot) Therapy Area Pipeline Report	March 2009	£790	27 %
Skin and Soft Tissue Infections Therapy Area Pipeline Report	March 2009	£790	27 %
Stroke_Central Nervous System Therapy Area Pipeline Report	March 2009	£790	27 %
Skin Infections or Dermatosis or Skin Itching Therapy Area Pipeline Report	March 2009	£790	27 %
Herpes Simplex Virus Infection Therapy Area Pipeline Report	March 2009	£790	27 %
Women's Health - Female Sexual Dysfunction Drug Pipeline Report	February 2008	£995	27 %
Peptic Ulcer or Gastric Ulcer or Duodenal Ulcer Therapy Area Pipeline Report	March 2009	£790	27 %
Thrombocytopenia or Idiopathic Thrombocytopenic Purpura Therapy Area Pipeline Report	March 2009	£790	27 %
Stroke_Cardiovascular and Circulatory System Therapy Area Pipeline Report	March 2009	£790	27 %
Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Drug Pipeline Report	February 2008	£1495	26.5 %
Non-Small-Cell Lung Cancer or Lung Cancer or Small Cell Lung Cancer Therapy Area Pipeline Report	March 2009	£790	26.5 %
Multiple Myeloma - Exploring New Targets For Multiple Drug Therapy Stakeholder Opinions	December 2007	£2005	25.9 %
Myelodysplastic Syndromes - First Approvals Spur Some Interest In A Niche Market Stakeholder Opinions	December 2007	£2005	25.55 %
Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Therapy Area Pipeline Report	March 2009	£790	25 %
Medivation, Inc. - Financial and Strategic Analysis Review	June 2009	£76	24.5 %
Molecular Insight Pharmaceuticals, Inc. -Detailed Product Pipeline	February 2008	£375	24 %
Therapeutics for Memory and Cognition Disorders	April 2009	£2960	23.5 %
Forecast Insight: Insomnia Orexin and serotonin receptor modulators to innovate market	August 2008	£7600	22.75 %
Stakeholder Opinions: Respiratory Syncytial Virus (RSV) A market yet to reach its full potential	December 2006	£2005	22 %
Stakeholder Opinions Respiratory Syncytial Virus (RSV) A market yet to reach its full potential	January 2007	£2005	22 %
Stakeholder Opinions: Biologics in Infectious Diseases Well Defined Target Populations Are Key to Commercial Success	March 2008	£2005	21 %
Stakeholder Insight: COPD - Another Reason to Quit	December 2005	£8695	20 %
Biologic Imaging Reagents Technologies and Global Markets	December 2008	£1915	19.6 %
Endometriosis - Scientific Clarity Will Unlock Market Potential Stakeholder Opinions	December 2007	£2005	19.25 %
Pipeline Insight: Therapeutic Cancer Vaccines A turbulent path from bench to bedside	December 2006	£6000	18.9 %
Stakeholder Opinions: Gastric Cancer Targeted Therapies Home In On a Neglected Tumor Type	March 2006	£2195	18.55 %
Addex Pharmaceuticals - Financial and Strategic Analysis Review	June 2009	£76	17 %
Stakeholder Opinions: Osteoarthritis Preconceptions Damage Awareness and Treatments	March 2006	£2195	16.8 %
Stakeholder Opinions: Cystic Fibrosis	March 2006	£2195	16.1 %
Pipeline Insight: Insulin Antidiabetics Return to Injections Alternative Delivery Methods Fall by The Wayside	July 2008	£6000	16.1 %
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007	June 2007	£1999	16 %
Stakeholder Opinions: Pancreatic Cancer - Gemzar dominance will continue among high levels of persistent unmet needs Healthcare	March 2009	£2000	15.75 %
Sepracor Inc. - Financial and Strategic Analysis Review	June 2009	£76	15.5 %
Stakeholder Opinions: Irritable Bowel Syndrome Potentially profitable market is open for the taking	June 2007	£1900	15.4 %
Pipeline Insight: Heart failure Week pipeline dominated by new indications and add-on diuretics	August 2007	£6000	15.4 %
Stakeholder Opinions: Irritable Bowel Syndrome Potentially profitable market is open for the taking	June 2007	£1900	15.4 %
The Future of the Orthopedic Devices Market to 2012	December 2008	£2135	15.4 %
Pipeline Insight: Orphan Diseases in Neurology Part III: Myasthenia Gravis	November 2008	£6000	15.05 %
Commercial and Pipeline Insight Vaccines for Adults and The Elderly - New Blockbuster Opportunities Ahead	July 2008	£7700	14.7 %
Commercial and Pipeline Insight Vaccines for Adults and The Elderly - New Blockbuster Opportunities Ahead	July 2008	£7700	14.7 %
Stakeholder Opinions: Pulmonary Arterial Hypertension clinical community builds order from chaos Healthcare	March 2009	£2000	14.7 %
Stakeholder Insight: Chronic Leukemias Is there room left for improvement?	November 2008	£8000	14.7 %
Stakeholder Insight: Acute Stroke - TPA spurs infrastructure changes for the better Healthcare	October 2007	£7600	14.7 %
Stakeholder Perspectives: Pulmonary Arterial Hypertension A small market gets big attention	February 2006	£4350	14.5 %
Stakeholder Opinions: Head and Neck Cancer Innovatives to Change the Face of Treatment	November 2007	£2005	14.35 %
Stakeholder Opinions: Sepsis The Critical Care Community Gains Critical Mass	March 2008	£2050	14.35 %
Stakeholder Opinions: Small Cell Lung Cancer and Malignant Mesothelioma Limited R&D activity provides opportunity for early-phase pipeline drugs	March 2007	£2005	14 %
Lexicon Pharmaceuticals, Inc. - Financial and Strategic Analysis Review	June 2009	£76	14 %
Stakeholder Opinions: Bone Metastases Impending Patent Expiries May Help Make or Break Newer Agents	March 2008	£2005	14 %
Pipeline Insight: Acute Stroke Commercial Risk Offsets High Unmet Need	May 2008	£6000	14 %
Colorectal Cancer: Pipeline/Commercial Insight Shaping the future dynamics of colorectal cancer management	October 2006	£8000	13.65 %
Pipeline Insight: Benign Prostatic Hyperplasia - Novel therapeutics and reformulations will drive market growth	April 2009	£6000	13.65 %
Keryx Biopharmaceuticals, Inc. - Financial and Strategic Analysis Review	June 2009	£76	13.5 %
Biomarkers The Expanding Global Market	November 2007	£2960	13.5 %
Stakeholder Opinions: Hepatocellular Carcinoma Opportune indication for novel therapies	June 2007	£3800	13.3 %
Pipeline Insight: Non-Small Cell Lung Cancer Pipeline set to offer only modest improvements	April 2008	£6000	13.3 %
Commercial Insight: HIV - The battle for market share is getting fiercer	August 2008	£7600	13.3 %
Forecast Insight: Dyslipidemia - Genericization and negative trial data drive market shrinking	August 2008	£7600	13.3 %
Stakeholder Opinions: Bladder Cancer New drugs needed to challenge ineffective 20 year old drugs	November 2008	£2000	13.3 %
Evotec Aktiengesellschaft - Financial and Strategic Analysis Review	April 2009	£76	13 %
Partnering with Biopharma The definitive guide to bigpharma partnering interests, contacts & agreements	July 2008	£1495	13 %
Blood-Brain Barrier Bridging Options for Drug Discovery and Development	May 2008	£685	12.95 %
Stakeholder Opinions: Gynecological Cancers Niche opportunities in advanced disease	December 2006	£2005	12.95 %
Siemens Medical Solutions Product Pipeline Analysis	August 2008	£460	12.95 %
Commercial and Pipeline Insight: Psoriasis Anti-TNF's lead another indication	December 2006	£8000	12.95 %
Forecast Insight: Multiple Sclerosis Tysabri to prevail despite safety setbacks	August 2008	£7600	12.6 %
Pipeline Insight: Breast Cancer Recent approvals increase pressure on pipeline candidates	April 2008	£6000	12.6 %
Innovations in Cancer Novel Therapeutics, New Diagnostics and Future R&D Strategies	February 2007	£1495	12.5 %
The Executive Guide to Molecular Imaging	July 2007	£595	12.25 %
Commercial Insight: Multiple Sclerosis Continued growth makes the MS market a highly attractive investment	June 2007	£7600	12.25 %
Stakeholder Opinions: Fibromyalgia Potentially lucrative market soon to become reality	May 2007	£2005	12.25 %
Stakeholder Insight Asthma - over-Prescribing Is Common in Intermittent and Mild Forms of Asthma	July 2008	£7600	12.25 %
Pipeline Insight: Asthma/COPD Targeted therapies on the horizon	November 2006	£6000	11.9 %
Stakeholder Opinions: Physician perception of biologics in autoimmune disease - Targeted detailing is the key to success Healthcare	March 2009	£2000	11.9 %
Pipeline Insight: Nosocomial Vaccines Minefield or Goldmine?	April 2008	£6000	11.9 %
Stakeholder Opinions: Systemic Lupus Erythematosus Market Set to Enter Era of Biologic Therapies	March 2008	£2050	11.55 %
Commercial Insight Antithrombotics Pipeline products to dampen the impact of patent expiries and cost containment initiatives	February 2007	£8000	11.55 %
Stakeholder Insight: Non-Small Cell Lung Cancer The need for greater product differentiation in an increasingly crowded market	November 2006	£8000	11.55 %
Commercial and Pipeline Insight: Hepatitis B	October 2007	£7600	11.2 %
Lymphoma A Therapeutic & Competitive Insight	May 2006	£1670	11 %
Chugai Partnering Guide 2008	July 2008	£195	11 %
Genzyme Partnering Guide 2008	July 2008	£195	11 %
Genentech Partnering Guide 2008	July 2008	£195	11 %
Forest Partnering Guide 2008	July 2008	£195	11 %
Eli Lilly Partnering Guide 2008	July 2008	£195	11 %
Gilead Partnering Guide 2008	July 2008	£195	11 %
GlaxoSmithKline Partnering Guide 2008	July 2008	£195	11 %
Lundbeck Partnering Guide 2008	July 2008	£195	11 %
King Partnering Guide 2008	July 2008	£195	11 %
Johnson Johnson Partnering Guide 2008	July 2008	£195	11 %
Eisai Partnering Guide 2008	July 2008	£195	11 %
Boehringer Ingelheim Partnering Guide 2008	July 2008	£195	11 %
Astellas Partnering Guide 2008	July 2008	£195	11 %
Amgen Partnering Guide 2008	July 2008	£195	11 %
Allergan Partnering Guide 2008	July 2008	£195	11 %
AstraZeneca Partnering Guide 2008	July 2008	£195	11 %
BMS Partnering Guide 2008	July 2008	£195	11 %
Biogen Idec Partnering Guide 2008	July 2008	£195	11 %
Bayer Partnering Guide 2008	July 2008	£195	11 %
Baxter Partnering Guide 2008	July 2008	£195	11 %
Merck Partnering Guide 2008	July 2008	£195	11 %
Merck Serono Partnering Guide 2008	July 2008	£195	11 %
Takeda Partnering Guide 2008	July 2008	£195	11 %
Solvay Partnering Guide 2008	July 2008	£195	11 %
Shire Partnering Guide 2008	July 2008	£195	11 %
Teva Partnering Guide 2008	July 2008	£195	11 %
UCB Partnering Guide 2008	July 2008	£195	11 %
Therapeutic Monoclonal Antibodies Report 2008-2023	July 2008	£1499	11 %
Wyeth Partnering Guide 2008	July 2008	£195	11 %
Watson Partnering Guide 2008	July 2008	£195	11 %
ScheringPlough Partnering Guide 2008	July 2008	£195	11 %
SanofiAventis Partnering Guide 2008	July 2008	£195	11 %
Novo Nordisk Partnering Guide 2008	July 2008	£195	11 %
Novartis Partnering Guide 2008	July 2008	£195	11 %
Mitsubishi Tanabe Partnering Guide 2008	July 2008	£195	11 %
Nycomed Partnering Guide 2008	July 2008	£195	11 %
Otsuka Partnering Guide 2008	July 2008	£195	11 %
Roche Partnering Guide 2008	July 2008	£195	11 %
ProcterGamble Partnering Guide 2008	July 2008	£195	11 %
Pfizer Partnering Guide 2008	July 2008	£195	11 %
Alcon Labs Partnering Guide 2008	July 2008	£195	11 %
CSL Partnering Guide 2008	July 2008	£195	11 %
Mundipharma Partnering Guide 2008	July 2008	£195	11 %
Ratiopharm Partnering Guide 2008	July 2008	£195	11 %
Menarini Pharma Partnering Guide 2008	July 2008	£195	11 %
Daiichi Sankyo Pharma Partnering Guide 2008	July 2008	£195	11 %
Abbott Labs Partnering Guide 2008	July 2008	£195	11 %
Barr Pharmaceuticals Partnering Guide 2008	July 2008	£195	11 %
Servier Partnering Guide 2008	July 2008	£195	11 %
Actavis Pharma Partnering Guide 2008	July 2008	£195	11 %
Stada Partnering Guide 2008	July 2008	£195	11 %
Commercial and Pipeline Insight: ADHD Immature adult market continues to offer greatest commercial potential	April 2008	£8000	10.85 %
Pipeline Insight: Upper GI Disorders - Generics will limit pipeline profit	July 2007	£6000	10.85 %
Stakeholder Opinion: Atopic Dermatitis A high level of unmet need creates market opportunities	March 2007	£2005	10.85 %
Stakeholder Opinions: Asthma Phenotypes A changing paradigm	March 2007	£2005	10.85 %
Pipeline Insight: Osteoarthritis The Wait for a DMOAD Continues	November 2006	£6000	10.5 %
Bigpharma Dealmaking Handbook Companies & Contacts	September 2008	£1195	10.5 %
Stakeholder Opinions: Ovarian Cancer Growing importance as secondary indication for targeted therapies	July 2006	£2195	10.5 %
Pipeline Insight: Epilepsy Pipeline drugs struggle to outshine their marketed predecessors	October 2006	£6000	10.15 %
Pipeline Insight: Non-insulin antidiabetics Incretin mimetics leaders in a diverse pipeline	May 2008	£6000	10.15 %
Antiageing and Life Enhancement Pharmacotherapeutics	January 2006	£4600	10 %
Pipeline Insight: Cancer Overview Increasing Diversity Offers Both High Risk And Reward	September 2007	£7600	9.8 %
Boehringer Ingelheim GmbH: PharmaVitae Profile	March 2009	£3010	9.8 %
Chugai Pharmaceutical Co. Ltd: PharmaVitae Profile	March 2009	£3010	9.8 %
Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents	October 2006	£2960	9.5 %
Triple Progress Analysis: Melanoma, Colorectal & Lung Cancer	March 2006	£2960	9.5 %
Stakeholder Opinions: Cystic Fibrosis - A pipeline full of hope Healthcare	March 2009	£2000	9.45 %
Merck KGaA: PharmaVitae Profile	March 2009	£3010	9.45 %
Pipeline Insight: Neuropathic Pain Emerging Drugs Fail To Capitalize In Lucrative Market	September 2007	£740	9.45 %
Commercial Insight: Select Herpes Viruses and Human Papilloma Virus Non-Biologic Interventions for Oral and Genital Herpes, Cytomegalovirus Infection, Herpes Zoster and Genital Warts	August 2008	£7600	9.45 %
Stakeholder Opinions: Cancer Cachexia Higher profile needed to unlock market potential of neglected syndrome	January 2009	£2000	9.45 %
Stakeholder Opinions: Tuberculosis - Development pipeline shows signs of life Healthcare	March 2009	£2000	9.45 %
Stakeholder Opinions: Melanoma Lucrative commercial opportunities persist	December 2006	£2005	9.1 %
Bigpharma Dealmaking and Agreements Handbook 2007 Companies, Contacts & Partnering Agreements	September 2007	£1195	9 %
Targeted Therapeutics in Non-Small Cell Lung Cancer	April 2007	£1340	9 %
Current and Future Therapies for Lung Cancer A Therapeutic & Competitive Insight	March 2006	£1670	9 %
Pipeline and Commercial Insight: Schizophrenia - Second generation depots protect market value	October 2008	£8000	8.75 %
Commercial and Pipeline Perspectives: Obesity Lack of Reimbursement Limits Market Potential	December 2006	£6000	8.75 %
Bayer Schering Pharma Ag PharmaVitae Profile	July 2008	£3010	8.75 %
Multiplex Assays in Translational Medicine Technologies, Applications, and Future Directions	February 2008	£685	8.75 %
Bayer Schering Pharma AG: PharmaVitae Profile	March 2009	£3010	8.75 %
Commercial and Pipeline Insight: HRT for Menopausal Symptoms A new class restores an old market	April 2008	£8000	8.75 %
Pipeline Insight: Hepatitis C Protease inhibitors to drive market expansion	June 2006	£6495	8.4 %
Shire plc: PharmaVitae Profile	November 2008	£3010	8.4 %
Pipeline Insight: Hematological Malignancies Companies target niche indications to facilitate market entry	April 2009	£6000	8.4 %
Amgen Inc.: PharmaVitae Profile Healthcare	March 2009	£3010	8.4 %
Forecast Insight: Opioids - Saturation limits the commercial potential of individual brands Healthcare	March 2009	£8000	8.05 %
Pipeline Insight: HIV Extending treatment options	September 2006	£6000	8.05 %
Pipeline and Commercial Insight: Anxiety Disorders Viable indication for antipsychotics companies	November 2008	£8000	8.05 %
Obesity Drug Markets in the US and EU Analysis of product pipelines and the competitive environment	July 2008	£1995	8 %
Hematological Cancers - A Therapeutic & Competitive Insight	October 2006	£2530	8 %
Commercial and Pipeline Insight: Systemic antifungals	November 2007	£7600	7.7 %
Commercial Insight: Pain Market Overview Non-Traditional Analgesics and Opioid Reformulations to Sustain Sector Growth	October 2008	£8000	7.7 %
Commercial Insight: Cardiovascular market overview Raft of patent expires threaten blockbusters	October 2007	£7600	7.7 %
Pipeline Insight: Molecular Targeted Cancer Therapies More pipeline activity, less product differentiation	November 2008	£8000	7.35 %
Pipeline/Commercial Insight: Supportive Care in Oncology Significant growth opportunities exist in new supportive care indications	June 2007	£7600	7.35 %
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries	July 2007	£7600	7 %
Commercial Insight: Antihypertensives New challenges for a maturing market	September 2006	£8000	6.3 %
Pipeline/Commercial Insight: Molecular Targeted Cancer Therapies More drugs on the market, more targets in the pipeline	October 2006	£8000	5.95 %
Strategic Perspectives: Antidyslipidemics Current market is not conducive for growth	October 2008	£8000	5.95 %
Pipeline and Commercial Insight: Nicotine Dependence - Chantix issues overshadow vaccine potential Healthcare	March 2009	£8000	5.25 %
Commercial Insight: Asthma & COPD Combination Products Still Have Blockbuster Potential	July 2007	£7600	5.25 %
Commercial Insight: Neuropathic Pain A Plethora of Patient Segmentation and Product Differentiation Opportunities	July 2006	£8440	4.9 %
Siemens Medical Solutions Medical Equipment Company Share Analysis	September 2008	£610	4.9 %
Stakeholder Insight: Supportive Care in Cancer Treatment Some first-generation products proving difficult to dislodge	October 2006	£8000	4.55 %

Search Results

Results for 'Pipeline Insight: Alzheimer's Disease'

Bookmark this Product